Inclusion Criteria:

- Patients aged 18 years of age or older at time of enrollment,

- Histologically proven and centrally reviewed CD52+ T-cell NHL Stages 2-4 including
the following nodal and extranodal subtypes:

Nodal:

- Peripheral T-cell lymphoma not otherwise specified (PTL NOS)

- Angioimmunoblastic lymphadenopathy (AILD)

- ALK 1 negative anaplastic large cell NHL

Extranodal:

- Hepatosplenic

- Enteropathy-associated

- Panniculitic

Exclusion Criteria:

- Previous treatment with chemotherapy or radiation with the exception of up to 1 cycle
of CHOP chemotherapy.

- Expected survival < 4 months.

- ECOG performance status > 3.

- Inadequate haematologic function (Hb < 85g/L, ANC < 1000/mm3, or platelet count <
75,000/mm3) unless directly attributable to the NHL.

- Inadequate hepatic function (total bilirubin > 35μmol/L, alkaline phosphatase > 2x UL
normal, AST/ALT > 2x UL normal)

- Inadequate renal function (serum creatinine > 130μmol/L), unless directly
attributable to the NHL.

- Non-measurable or non-evaluable disease, according to criteria of Cheson et al49.

- Geographically inaccessible for follow-up

- Known hypersensitivity to study drugs

- Serious illnesses that may interfere with subject compliance, determination of
causality of adverse events or would compromise other protocol objectives.

- Known HIV positivity or other pre-existing immunodeficiency (e.g., post-organ
transplant).

- Known CNS involvement with lymphoma (tests to investigate CNS involvement are
required only if clinically indicated).

- Pregnant or lactating women.

- Women who are of childbearing potential but are not using effective contraception.
Men with reproductive potential who are not using effective contraception.

- Previous malignancy within the last 5 years with the exception of cervical carcinoma
in situ or non melanoma skin cancer.

- Nasal natural killer (NK) T-cell NHL